Editors

Dr. Sudhanshu Abhishek 
Johns Hopkins University School of Medicine
USA

Research Interest: Imaging, Pathogenesis of Infectious Diseases-Tuberculosis, Host-pathogen interactions​, Host-directed therapy in a ​pre-clinical model of TB.

Biography:
Jul 2018 - Current
Post Doctoral Researcher
Johns Hopkins Medicine
Baltimore, United States

Post Doctoral Researcher
Post Graduate Institute of Medical Education and Research (PGIMER)
Chandigarh, India

Education
Doctorate in Tuberculosis
PGIMER, Chandigarh, Biochemistry, Dr. Indu Verma's Lab

Honors & Awards
NIH-Fogarty Fellow, NIH, USA

Society Memberships
Mar 2018 - Present  Postdoctoral membership, American Society for Microbiology

Professor and Academic Tenure of Chemistry &
Director of the BioSpectroscopy Core Research Laboratory at
Faculty of Chemistry, California South University (CSU), Irvine, California, USA 
&
President of American International Standards Institute (AISI)
Irvine, California, USA

Research Interest: Pharmaceutical Chemistry, Molecular Modelling, Anti–Cancer Nano Drugs, ATR–FTIR Spectroscopy, Medicinal Chemistry, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation

Biography: Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Distinguished Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than four hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI), PubMed and Scopus Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, New Zealand, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Ukraine, Turkey, France, Swiss, Germany, Sweden, Norway, Italy, Austria, Czech Republic, Hungary, Poland, South Africa, Egypt, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Indonesia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than one thousand reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international and peer–reviewed journals, books and publishers. Hitherward, he is a member of more than four hundreds reputed international academic–scientific–research institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA. 

President Foundation T. & L. de Beaumont Bonelli for Cancer Research, Naples, Italy.
&
Chairman of the VirusSphere World Academy of Biomedical Technologies (WABT) UNESCO, Paris, France.

Research Interest: Tumor vaccines, Hepatitis B vaccine, Poliovaccine, Immunotherapy, Human Immunodeficiency Virus (HIV), Herpesviruses, Virus-induced tumour antigens, Respiratory Syncytial Virus, Adenocarcinoma.

Biography: Prof. Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President Foundation de Beaumont Bonelli for Cancer Research. His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer.Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

 •    1964-1966 - Assistant, Institute of Pathology, University of Naples
•    1965-1968 - Research Associate, Division of Virology and Cancer Research, The Children's Hospital       Research Foundation, Cincinnati, Ohio: Albert B. Sabin, M.D.
•    1968-1969 - Assistant Professor of Research Pediatrics, University of Cincinnati, College of Medicine
•    1966-1974 - Italy National Research Council Fellow; Research Chief( 1974 )
•    1971-1985 - Professor of Oncologic Virology, University of Naples, l st College of Medicine
•    1971-1975 - Project Director (National Cancer Institute, Bethesda. Md, U.S.A.) Research Contract n. 712056 (1971-1972) and n. NO1 CP33315 (1973-1975)
•     1972- to date Professor of Microbiology and Immunology at the School of Specialization in Medical Nephrology, Ist College of Medicine then 2nd University of Naples (S.U.N.)
•    1973 - to date Chief, Division of Virology, "D. Cotugno" Hospital for Infectious Diseases
•    1973- Senior Scientist, N.C.I., FrederickCancerResearchCenter, Fort Detrick, Frederick; Maryland
•    1975-1979 - Representative of the Education Minister in the Scientific Committee of the Zoological Station (Aquarium) of Naples
•    1978 - Life President of the “Teresa and Luigi de Beaumont Bonelli Foundation for Cancer Research” (Italian Presidential Decree, Jan. 3, 1978)
•    1995-98 Member of National Commitee on Bioethics 
•    1998 - to date - President Ethic Committee of D.CotugnoHospital
•    2000-2003 Scientific Coordinator of Extracorporeal Hyperthermia in HCV Patients, First Circle
      Med., Minneapolis, USA
•    2003 - to date - Head Department of Diagnostic Laboratories of D.Cotugno Hospital 
•    2004 - to date President of “Campania Technology and EcologyCenter”
•    2005 Vice-Chairman and General Secretary of the Scientific Advisory Board of Unihart Biotech Pharma, N.V. (www.unihart.com) 
•    2005 – Member of Ethic Committee of Basilicata Oncologic Hospital
•    2006 – Emeritus Chief, D. Cotugno Hospital for Infectious Diseases
•    2007 – Chairman Committee on BioTechnologies and VirusSphere, World Academy of Biomedical Technologies (WABT), UNESCO – Paris 
•    2007 - Adjunct Professor Department of Biology, Center for Biotechnology - College of Science and Technology, TEMPLEUNIVERSITY – PhiladelphiaUSA

Italian Soc. Immuno-Oncology (v.p. 1975-, pres. 1990-2008), Internat. League Drs. for Abolition of Vivisection (pres. 1992-2012), Internat. Assn. Leukemias, Am. Assn. Cancer Rsch., Am. Soc. Microbiology (people to people amb to South Africa 2010), Acad. History Sanitary Art (hon.), Rotary, Lions (pres. Pompei chpt. 1987-89, pres. com. fight cancer 1989-90, vice gov. dist. 1991-92, pres. com. fight cancer 1992-94, pres. com. sci. and life 1994-95, pres. com. fight drug addiction and AIDS 1995-97. pres. com. transplant and donations 1998-99, pres. com. oncology 2000-02, pres. com. on stem cells 2002-03, dist. dir. operative area ethics and social solidarity 2003-04, pres. Pompei chpt. 2004-06, dist. dir. operative area health and rsch. 2006-14, dist. dir. rare diseases 2014-15, LISC Internat dir. 2012-14, Melvin Jones fellow 1993,2004,2008,2010, 1995). Roman Catholic. Achievments include patents in fieldof first link-at-viruses to human cervical cancer; discovery ofRSV virus in infant deaths in Naples and of tumor liberated protein as a tumorassociated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas. Flu virus expert 2015 (OMICS Group). Home Via Posillipo 286 80123 Naples NA Italy. He published more than 500 scientific papers.

Department of Microbiology, 
Immunology and Veterinary Public Health, 
Founder of Narayan Consultancy on Veterinary Public Health and Microbiology, 
India. 

Research Interest: Infectious Disease, Pathogens, Medical Microbiology, Immunology

Biography: Prof. Mahendra Pal, an internationally renowned scientist and a well-known distinguished academician, has published 520 scientific papers and authored 7 books to his credit. Prof. Pal guided over 67 students at DVM, MSc and Ph.D. level in India and Ethiopia. He is credited to develop Sunflower seed agar (Pal medium) medium, APRM medium, PHOL stain and Narayan stain for the study of fungi. Prof. Pal elucidated for the first time the role of Cryptococcus neoformans in the mastitis of goat and buffalo, Fusarium solani in corneal ulcer of buffalo, Aspergillus fumigatus in rhinitis of camel and mule, Trichophyton verrucosum in dermatitis of deer, Candida tropicalis in human lung empyema, Nocardia asteroides in keratitis of cattle. He has established for the first time the prevalence of Cryptococcus neoformans in the environment of New Zealand, Nepal, and Djibouti. He has reported the first isolation of Candida albicans from mastitic milk, and Trichophyton verrucosum in dermatitis of camel in Ethiopia. Prof. Pal biography is published in World Who and Who. He has travelled to several countries such as New Zealand, Belgium, Japan and Ethiopia for delivering guest lectures and undertaken collaborative research works. Prof. Pal is the recipient of “Distinguished Teacher Award”, and “Jawaharlal Nehru Award”. Indian Association of Veterinary Public Health recognized the laudable contributions of Prof. Pal in the field of Veterinary Public Health and conferred him with Lifetime Achievement Award”. He is the First Asian to work as “Deputy Editor†of Mycoses, published from Germany. In addition, he is serving as a Honorary Editor, Associate Editor, and Member of the Editorial Board of many scientific journals. Prof. Pal is the First Indian Veterinarian who worked as JSPS Visiting Scientist†at University of Tokyo, Japan. He is serving as Member of Infectious Diseases working Group of EAZWA, Switzerland. Prof. Pal was instrumental in starting Ph.D. programme in Veterinary Public Health at Anand Agricultural University, India and also at Addis Ababa University, Ethiopia. Prof.Pal was awarded Fellow by National Academy of Veterinary Sciences, and also by Korean Society of Veterinary Clinical Medicine, Seoul, South Korea. Very recently, Indian Association of Veterinary Public Health Specialists has instituted an award in the name of Prof. Pal to remember his outstanding, immense, commendable and significant contributions in science.The name of award is a Prof.Mahendra Pal Award in Zoonoses, which is given every year during National Conference of Veterinary Public Health to a scientist, whose research is judged best by panel of Experts. Prof. Pal is known as “Father of Veterinary Mycology in India. 

Department of Pediatric Allergy-Immunology, 
Sakarya University School of Medicine, Training and Research Hospital, 
Turkey

Research Interest: Allergy, Clinical Immunology, Pediatric-Immunology, Immunostimulants, Cytotoxicity, Rotavirus Vaccines

Biography: Prof. Dr. Oner Ozdemir was born in Alaplı, Zonguldak, Turkey in 1965. He has graduated from İstanbul Medical School, İstanbul University and become a medical doctor in 1989. Dr. Ozdemir did his pediatric residency at Department of Pediatrics in Children’s Hospital, İstanbul Medical School, İstanbul, Turkey. His clinical fellowship training was completed at Pediatric Allergy/Immunology division in Louisiana State University, Health Sciences Centre, New Orleans, LA. Some part of his clinical fellowship training was done at Pediatric Allergy/Immunology program in Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Dr. Ozdemir bench research areas are as follows: LAK-cell generation and cell-mediated cytotoxicity; human mast cell development and mast cell-mediated cytotoxicity; and apoptosis related research. Dr. Ozdemir clinical research areas are as follows: hereditary angioedema, chronic uricaria, biological agents. He was the first place winner of Clemens Von Pirquet Award from ACAAI at ACAAI meeting in 2005 for the best research on allergy/asthma/immunology by a fellow in training. Dr. Ozdemir has more than 75 international plus 70 national publications, as well as 145 international and 130 national presentations, and more than 9 chapters related to my research areas. He have been an editor of 4 books so far. Currently, he works as a head of pediatrics and the division of pediatric allergy/immunology at Medical Faculty of Sakarya University, Sakarya Research and Training Hospital, Adapazarı, Sakarya, Turkey.

Distinguished Alumnus The Ohio State University
Chairman Emeritus
Past President and CEO
Biological Mimetics, Inc.
Frederick, USA

Research Interest: Virology, AIDS, Vaccine, Immunology, Comparative microbiology, Pathogenesis, Retrovirology

Biography: Dr. Nara holds a M.Sc. in Immuno-pharmacology, a combined Doctor of Veterinary Medicine and Ph.D. (retro-virology/oncogenesis) from The Ohio State University, 4 year combined residency in Comparative Pathology and NIH post-doctoral Fellowship at the Armed Forces Institute of Pathology and a NIH respectively. Dr. Nara currently holds the Endowed Eugene Lloyd Chair, Professor in Vaccinology, founding Center Director for the Center for Advanced Host Defense, Immunobiotics, and Translational Comparative Medicine in the Department of Biomedical Sciences, in the College of Veterinary Medicine at Iowa State University and also the Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc.,. He is also an distinguished Alumni of The Ohio State University College of Veterinary Medicine and an elected Fellow of the American Association for the Advancement of Science in 2011. His comparative medical research interests are to more fully understand how early and pre-determined events in the host innate and acquired immune systems are sculpted and bias the development of protective long lasting responses against infectious pathogens and cancer and more importantly  developing new technologies and strategies to circumvent the non-protective immune responses for the development of novel classes of immunobiotics and vaccines focused on the prevention of disease and are translating these into viably products via a new academic- private-commercial model. He has been and continues as National and International member of numerous programs at the National Academy of Science, Institutes of Medicine, National Institutes of Health, Department of Defense, and Centers for Disease Control AIDS, World Health Organization, United Nations Global AIDS Characterization program–related and infectious diseases national planning, human and animal agricultural biodefense, vaccine development & policy reporting meetings involving pathogenesis, vaccine discovery, standardization, correlates of protection committees and consults and serves on numerous scientific advisory boards of corporate, private foundations and academic initiatives in the area of national biodefense, comparative medicine and immunology, vaccine discovery and immuno-therapeutics and a recent member of the U.S. State Department Bio-Industry Initiative Program, The Civilian Research and Development Foundation (CDRF) and The International Science and Technology Center (ISTC) for non-proliferation of biological agents. He published more than 200 publications and has 61 Book Chapters/Reviews.

Professor of the Department of Pathology,
Federal University of Minas Gerais Belo Horizonte,
Brazil.

Research Interest: Cellular Biology, Pathology, Medical Bacteriology 

Biography: Dr. ALEXANDER BIRBRAIR is affiliated to the Department of Pathology, Federal University of Minas Gerais. Dr. ALEXANDER BIRBRAIR is currently providing services as Research and in Academics. Dr. ALEXANDER BIRBRAIR has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. ALEXANDER BIRBRAIR contributions have acclaimed recognition from honourable subject experts around the world. Dr. ALEXANDER BIRBRAIR is actively associated with different societies and academies. Dr. ALEXANDER BIRBRAIR academic career is decorated with several reputed awards and funding. Dr. ALEXANDER BIRBRAIR research interests include Techniques for Diagnoses of Intestinal Parasites,Cellular Biology,Medical Bacteriology,Pathology. He published more than 100 scientific publications.

HONORS AND AWARDS
2017. Won the prestigious Instituto Serrapilheira Grant 2017-Call
2017. Elected Affiliated Member of the Brazilian Academy of Sciences
2015. Recipient of Gordon A. Melson Outstanding Doctoral Student Award for 2015
2014. Winner of 3-minute thesis (3MT) oral competition (2014 Fourteenth Annual Wake Forest University Graduate Student & Postdoc Research Day)
2014. Editor's choice in Journal of Gerontology Biological Sciences Volume 69 Issue 12 December 2014 for the manuscript “Human Slow Troponin T (TNNT1) Pre-mRNA Alternative Splicing is An Indicator of Skeletal Muscle Response to Resistance Exercise in Older Adults.” by Zhang T, Choi SJ, Wang ZM, Birbrair A, Messi ML, Jin J-P, Marsh AP, Nicklas B, and Delbono O.
2013. Awarded with the Glenn/AFAR Scholarship for Research in the Biology of Aging
2012. Wake Forest University Graduate and Postdoctoral Students Research Day (Troponin T nuclear localization and its role in skeletal muscle aging) (12th annual competition) (First place) (Co-author)
2008. “Metagenome of soil contaminated with petroleum.” Scholarship from : Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB), Brazil.
2006. “Best poster (Genetic diversity between isolates of Chromobacterium violaceum) presented in the area of biological sciences during the XII Seminário de Iniciação Científica da Universidade Estadual de Santa Cruz – UESC, Ilhéus – Bahia.”

CEO & Founder
R&D pharmaceuticals
Belgium

Research Interest: Vaccines, Adjuvants, Immunostimulants, Antigen delivery, DNA- & RNA-based vaccines, Viral vectors, Viral-like-particles, Nanoparticles, Mucosal administration  of vaccines (Oral, Nasal, skin), Antibody and cellular-mediated immune responses, Efficacy animal models, Toxicity studies, Early  clinical studies. 

Biography: Dr. Abdelatif Elouahabi Obtained a Bachelor in Animal Biology from the University "Abdelmalik Essadi" (Morocco, 1989) and a Master in Molecular Biology and Biotechnology from the  Free University of Brussels (Belgium, 1992). His PhD was in gene transfer and expression using viral and non viral vectors and the research leaded to discovering key cellular and molecular parameters governing exogenous nucleic acid entry and expression into cells. His post doc was focused in studying mechanisms   of lipid vector-mediated intravenous  gene delivery into animal models as well applications for gene therapy and vaccination. This work allowed identification of the role of plasma proteins and lipoproteins  in modulating lipid vector/DNA target organs and cells as well as the inflammatory processes induced by the gene delivery. In 2005, Dr. Elouahabi joined GSK vaccines where he played a key role in developing novel and potent adjuvants for new vaccines in both the infectious diseases  and cancer  fields. He had been also leading evaluation of external new vaccine  technologies   across the world. Today, Dr. Elouahabi is acting as a senior  R&D consultant for  biotech compagnies actives in developing gene therapy and vaccines pharmaceutical products. 
 

GSK’s Global Medical Affairs Director
USA

Research Interest: Immunology, Immuno-dermatology, Infectiology, ds-RNA vaccines, life virus vaccines, Immunomodulators, MMRV, Rotavirus, Norovirus, Diarrheal disease, Vaccinolgoy.

Biography: Dr. Bernd Benninghoff has been involved the medical, pharmaceutical, biology, immunology, chemistry and oncology fields for more than 30 years. He has worked in various leading positions in global pharmaceutical companies. He became involved in GSK’s Global Medical Affairs because he had always wanted to explore the benefits and education of people on the value and importance of preventive medicine. As a co-founder and past-CEO of BioMed-Klinik, he expressed his aspiration to work in research. He initiated more than 100 clinical trials in different therapeutic areas, such as respiratory, central nervous system, cardiology, dermatology, oncology and infectious disease, where he made inventions, filed patent letters and issued various publications. With GSK, Bernd is responsible for the evidence generation and strategic positioning of the Human Rotavirus Vaccine, which is launched in more than 130 countries with more than 250 Million infants being vaccinated. He contributed to introduce this vaccine into the public immunization programs in up to 90 countries within less than 15 years after the initial registration, which is anticipated to reduce childhood mortality and morbidity.
Dr. Benninghoff is specialist in Immunology as well as a graduated Biologist and Chemist. He was trained at the University of Köln and University Bielefeld. Dr.Benninghoff received his Ph.D. degree form University of Heidelberg, Institute for Immunology and Genetics, Deutsches Krebsforschungszentrum (German Cancer Research Centre), where he also conducted medical studies. 

Istituto Superiore di Sanita
Italy

Research Interest: Infectious diseases epidemiology,Emerging infections, Vaccines and immunization, Vaccines for emerging infections, Vaccination coverage, Efficacy, Effectiveness, and Adverse reactions.

Biography: Dr. Giovanni Rezza, M.D., specialized in hygiene and in infectious diseases, is the Director of the Department of Infectious Diseases at the Istituto Superiore di Sanità (ISS) in Roma, Italy. His main background is in infectious disease epidemiology. His main area of expertise includes HIV and other emerging infectious diseases (such as Chikungunya, West Nile, influenza), and vaccination strategies.
He has worked for the Italian Ministry of Health, the World Health Organization in Geneva, the Italian Cooperation, and the European Union. He has been contract professor at the University of Sassari and ran courses at the University of Roma (“La Sapienza” and “Tor Vergata”). He has been Chairman of the Administration Board - and he is now President of the Scientific Board - of the Consortium called “Collezione Nazionale dei Composti Chimici e Centro Screening” (CNCCS), a public/private initiative including ISS, National Research Council, and IRBM. He served as a member of several national and international committees and is currently member of the Italian NITAG. 
He has carried out epidemiological investigations in Italy and abroad, regarding both community and hospital outbreaks. He has been the principal investigator of several research projects and is author of more than 400 articles indexed in PubMed, and 4 books.
Finally, he is the editor of the “infectious disease epidemiology” section of BMC Public Health, has a member of the Editorial Board of “AIDS” for a six years period, Editor of the supplement of “AIDS” for two years, and is acting as a reviewer for several international scientific journals.
 

Physician - Clinical and Research,
European Society of Cardiology,
France

Research Interest: Infective Endocarditis, Immunocompromise and occurrence of latent infections, Prevention and Vaccination of viral influenza and other viral infections in Heart Failure. 

Biography: Working expertise in Cardiology and Tropical Medicine and in both clinical and Research. I am a scientific working group member and physician on Myocardial and pericardial disease, Clinical trial and of in European Society of Cardiology. I am also a working member on cardio-oncology and Cardiovascular Pharmacotherapists and Trialists of Tomorrow (CPTT). I am now a working member of EURObservatory Long Term Registry of Infective Endocarditis and Myocarditis and Infection of Heart in developing countries.
 

Director
R&D heading conjugate vaccine research,
MSD Wellcome Trust Hilleman,
India.

Research Interest: Vaccines, Conjugate, Polysaccharide, Technology transfer, Bioanalytics, Immunoassays.

Biography: Dr. Manoj Kumar, (Ph.D., Bacteriology) is working as Director, R&D heading the conjugate vaccine research at MSD Wellcome Trust Hilleman Laboratories in New Delhi. In his 17 years of research career, he has worked on different stages of development of several vaccine candidates, biosimilar products and diagnostics from concept till pre-clinical development and regulatory submissions. His major contributions come in research and development of multivalent pneumococcal, meningococcal and H. influenzae type b conjugate vaccines, acellular pertussis vaccine, mono/multi-plexed immunoassays/PCRs, monoclonal antibodies against polysaccharides and proteins. He has led technology transfers of various production processes and analytical methods from R&D-R&D, R&D-QC and R&D-Manufacturing. He has participated in expert group meetings focused on pneumococcal vaccine and epidemiology conducted by WHO, ICMR and ASIP group. He is a contributing scientist for WHO TRS977 Annex 3 for recommendations to assure quality, safety and efficacy of pneumococcal conjugate vaccines and 3 WHO expert reports. He has 12 granted patents, >47 patent applications, 14 peer reviewed publications, 2 book chapters, 4 popular articles, several gene sequences, 12 national/international awards in his name. He is member of editorial boards of 2 scientific journals and has reviewed for 16 journals including Vaccine, Carbohydrate Polymers, Biologicals and Biotechnology Progress. His focus areas include: New vaccine development; Cost effective vaccine technologies; Developing rapid analytical methods, Technology transfers and Business development. He further has keen interest in local skill development and has guided several university students as industry mentor.

National Agency for Medicines & Medical Devices
Albania

Research Interest: Safety of vaccines, Regulatory issues, AEFI, Efficacy

Biography: Dr. Merita KUCUKU has studied PhD from 2007 – 2010: “Study and chemical- analytical evaluation of some vaccines used in Albania”,
2003- 2006 study of Master and graduated MSc.
Actually is working  Head of Control Lab in National Agency for Medicines & Medical Devices (NAMMD)
May 2013- April  2018 analyst in NAMMD involved in regulatory issues,  safety and efficacy of vaccines. 
Nov. 2006-  2012 Head of National Regulatory of Vaccines in National Center Drugs Control
2005-2006 Analyst in NRA in Institute of Public Health
Trained for safety of vaccines, quality control of vaccines, GMP, instrumental analysis in Laboratory, Environmental Impact Assessment etc.
Participant in meetings and workshops arranged from WHO, Merieux Foundation, NIH etc. for vaccines issues.
Participant in national & international conferences where presented her presentations for pharmacovigilenca, regulatory issues, safety of vaccines etc.
Author of articles published in international and national journal
Feb.  – May 2018, National Expert on:”Identification of populations at risks and gender dimensions”, for the  Minamata Initial Assessment for Albania (MIA) Project-  UNDP
Partner of Brighton Collaboration
2018                               Member of  Working Group (WG)Neonatal Seizures, GAIA project
May 2014- 2016             Member of working group for Case Definition - Vasculitis, arranged 
                                        from AIFA-Italy & Brighton Collaboration 
Jan. - Jun. 2016               Member of Abortion WG for safety of the Global Alignment of   
                                        Immunization Safety in Pregnancy (GAIA Project)
2006-2012                       Member of ICC in Albania
2007                                Focal Point of NRA

Founder and Chairman Emeritus; Vaccinogen, Inc.
USA

Research Interest: Cancer Vaccines, Lymphatic Tissue, Germinal Centers, Mechanism of Humoral Immunity, Bacillus Calmette Guerin (BCG), Bladder Cancer, Cancer Genomic Heterogeneity, Cancer Diversity, Active Specific Immunotherapy, Tumor Antigens, Autologous Tumor Cells, OncoVAX.

Biography: Dr. Michael G Hanna, Jr. received his PhD in experimental pathology and immunology from the University of Tennessee (TN, USA) in the 1960s. He was a consultant with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during 1974–83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA). He was Chief Operating Officer during 1985–94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, Netherlands. He developed and obtained approvals for TICE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer before it merged with Intracel Corp. in 1998. He continued to work for Intracel Resources as Chief Scientific Officer and Chairman.
In 2007, Dr. Hanna founded Vaccinogen Inc., where he served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus. The company is a pioneer in the field of cancer vaccines and is
developing OncoVAX, an autologous vaccine designed to elicit a specific immune response against cancer cells. The Phase 3 vaccine is being investigated for treatment mainly of colon cancer, but also for melanoma and renal cell carcinoma. In addition to cancer therapy research and development, Dr. Hanna has been involved in Homeland Security. He served as Chairman of the Department of Commerce Biotechnology Advisory Committee (1984–9) and also participated in the Department of Defense Technical Working Group for Biotechnology (1988–9). PerImmune completed a Department of Defense contract to manufacture the current effective therapeutic for Botulinum toxin, an equine heptavalent anti-toxin. Dr Hanna’s research resulted in over 225 publications in international peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy. Dr Hanna has been the recipient of numerous honors and awards and has served on many editorial boards, including for Human Vaccines & Immunotherapeutics.

Research Interest: Immunization, Public Health, Healthcare, Health Care Management, Health Services Research, Population Health, Health Care Delivery, Healthcare Quality, Health Promotion, Human Resources For Health

Biography: Dr. Randa S. Hamadeh is the head of the Primary Health Care and Social Health Department, and Manager of The Immunization and Essential Drugs Programs, at the Lebanese Ministry of Public Health.  She is an internationally renowned Public Health Expert and Consultant. She has coordinated most of the Health Emergency Initiatives in Lebanon during the Syrian Crisis. She is currently leading and coordinating the Universal Health Coverage Project run jointly with the World Bank. She contributed with unique leadership to creating a PHC network in Lebanon through which preventive programs and community health initiatives are launched, involving local municipalities and NGOs. She leads to the introduction of the PHC facility accreditation program in Lebanon in 2008, and she is the vice chair of the national accreditation committee. She has numerous Publications and Research findings, some of which are taught among others at Oxford University. She contributes yearly as a lecturer and a panelist to International conferences in Public Health and Vaccines and she is an ADVAC (Advanced vaccinologist) member and an active participant in SAGE (Strategic Advisory Group of Experts) Global meetings. She is a member of various National Vaccines and Public Health technical committees. She has been an active contributor, in her capacity as a Primary Healthcare Expert  and Lecturer  to the 36Th anniversary of ALMA ATA Declaration in 2012. In 2014, she was nominated for the UNHCR Nansen Refugee Award In June 2017 Dr. Hamadeh was elected for a Public Health Excellence Award, Delta Omega Honorary Society of Public Health from the American University of Beirut. In 2017 she was unanimously nominated for the Randa Bdeir Leadership Award at AUB, an award established in recognition of outstanding leadership in supporting the careers of women. In 2017, the Arab league, and The Arab Hospital Federation nominated Dr Hamadeh as the “Ambassador of Health in the Arab Countries” . She has actively participated in the foundation of various NGOs. Dr. Hamadeh has successfully promoted the partnership between the ministry of Health and the Academia. She is the preceptor of AUB Public Health students joining the PHC department for their residency programs since 2011. She holds an MPH degree, a Vaccinology Diploma and a PhD in Public Health.

Senior Scientist
Forest Pathology Department
KSCSTE-Kerala Forest Research Institute (KFRI)
India

Research Interest: Medical Mycology, Fungal Vaccines, Immunotherapeutics, Fungal taxonomy, Phytopathogenic Fungi

Biography: Dr. Shambhu Kumar is presently working as a Senior Scientist at Department of Forest Pathology, KSCSTE-Kerala Forest Research Institute, Kerala, India. He obtained his Ph.D. degree in Botany (Mycology) from Deen Dayal Upadhyay Gorakhpur University, India. He has over ten year’s research experience. Dr. Kumar is the recipient of Fast Track Young Scientist award by SERB-DST, Government of India and worked at Birbal Sahni Institute of Palaeobotany, Lucknow. 

He has published over fifty research papers in peer-reviewed and reputed international and national journals. He has participated and presented papers in several international and national conferences/workshops and acquired national training on Biodiversity, Bioinformatics and Molecular taxonomy. He is a member of the International Society for Fungal Conservation (ISFC), UK and Life member of the Mycological Society of India, and Society for Basic and Applied Mycology. He is an Editorial member and reviewer of various international and national journals.

Professor
Faculty of Medicine
Hainan Medical University
China

Research Interest: Tropical medicine, Vaccination, Laboratory science (biomedical), Nanoscience and nanotechnology, Bioinformatics and medical engineering, Family medicine, Social medicine and public health.

Biography: Prof. Viroj Wiwanitkit is a University Professor, Visiting University Professor, Hainan Medical University, Hainan China/ Visiting Professor, Faculty of Medicine, University of Nis, Serbia/ Special Lecturer, Chulalongkorn University, Bangkok Thailand/ Adjunct Professor, Joesph Ayo Babalola University, Nigeria/ Professor, Senior Expert, Surin Rajabhat University, Surin, Thailand. Board of Family Medicine, Thai Medical Council, Fellowship of Clinical Scientist Association, USA (invited), Fellowship of International Society of Gene therapy and Molecular biology (invited), Fellowship of International Society of Cancer Therapy (invited), Membership of European Society of Pediatric Nutrition (invited). • Invited reviewer of many regional and international medical and science journals, Invited speaker in many International Congress.
Publications
More than 1,500 publications in the international journal (in science and medicine index such as Scopus, PubMed, Medline, ChemAbstract and ISI)
More than 150 presentations in international congress (as Key note Speaker and Session Speaker)
Invited chapters in many international textbooks (more than 150)
Many textbooks in Thailand and International level (more than 30)

Laboratory of Vaccine Development - Instituto Butantan
Brazil

Research Interest: Bioprocessing, Vaccine production and process, Recombinant protein, Antigen purification, Vaccine quality control, Microbial cultivation

Biography: Degree in Industrial Pharmacy (1991), Master’s Degree in Biotechnology (1997) and Ph.D. in Biochemical-Pharmaceutical Technology (2002) at the Universidade de São Paulo. Post-doctoral fellow at Pasteur Institute, Paris, France, with a fellowship from CNPq (2005). Scientific researcher at Instituto Butantan, São Paulo, SP, Brazil, since 1993. Expertise in the field of Biotechnology focusing in development of bioprocessing for production and purification of pharmaceutical molecules, mainly vaccine antigens, such as: capsular polysaccharides of Streptococcus pneumoniae, inactivated whole cell vaccine against S. pneumoniae, recombinant proteins of pneumococcus and Zika virus in high cell density cultures of Escherichia coli. The recombinant E. coli platform is also applied for production of human therapeutic proteins as granulocyte colony-stimulating factor and interferon. Recently, she is involved in a project for production of recombinant bacillus Calmette-Guérin as a live attenuated vaccine and participates of a scale-down project for the optimization of hepatitis B vaccine production in recombinant yeast Pichia angusta. She has supervised 07 Master’s Degree thesis as principal supervisor and 02 as co-supervisor, 03 Ph.D. thesis as principal supervisor and 01 as co-supervisor, and 01 post-doctoral fellow. She is currently supervising 03 Ph.D. students, 02 Master’s Degree student and 01 undergraduation student.

Employment history: Feb 1992-Out 1993 – Training at Centre of Biotechnology, Instituto Butantan, Sao Paulo, Brazil, scholarship from Sao Paulo State government (FUNDAP)
Nov 1993-present – Scientific Researcher at Laboratory of Vaccine Development (former Centre of Biotechnology), Instituto Butantan, Sao Paulo, Brazil. Instituto Butantan is an organization of the Sao Paulo State government.

Educational Qualifications: Feb 1988-Dec 1991 – Degree in Industrial Pharmacy
Faculdade de Ciências Farmacêuticas de Ribeirão Preto – Universidade de São Paulo
Jul 1993-Feb 1997 – Master’s Degree in Biotechnology – Universidade de São Paulo; advisor: Dr. Luciana C. C. Leite; MSc thesis title “Purification of catalase from human placenta”
Mar 1998-Jul 2002 – Ph.D. in Biochemical-Pharmaceutical Technology, emphasis in Fermentation Technology – Universidade de São Paulo; advisors: Dr. Martha Massako Tanizaki and Prof. Dr. Roberto de Campos Giordano; Ph.D. thesis title “Development of an industrial method of polysaccharide production by Streptococcus pneumoniae for vaccine formulation”
Aug-Set 2002 – 15º ITP course: “From gene to vaccine” at German Research Centre for Biotechnology (GBF), Braunshweig, Germany
Out 2003-Feb 2005 – Post Doctoral Fellow at Institute Pasteur, Paris, France; advisor: Dr. Pierre Béguin, Plateau Technique n° 5 “Production and purification of recombinant proteins and monoclonal antibodies”

Assistant Professor, 
Department of Eastern Medicine, 
Directorate of Medical Sciences, Faculty of Science and Technology
Government College University Faisalabad
Pakistan

Research Interest: Hyperuricemia, Xanthine oxidase inhibition by some selected medicinal plants, Enzyme Inhibition, Study of traditional system medicine (Indusyunic Medicine) Phytochemistry, and poisonous plants, Bioactivity and phytopharmaceutical evaluation of herb drugs and their natural products, Medicinal plants and Clinical trial, Biochemistry, Bioinformatics

Biography: COURSES TAUGHT FROM 2006 TILL DATE Biochemistry Bioinformatics Microbiology and Parasitology General Pathology Clinical diagnostics Surgery COURSES TAUGHT TO M. PHIL Rational Phytotherapy Basic Therapeutics Internal Medicine Advance Therapeutics PROFESSIONAL STATUS Registered Tabib (Registration # QBH-111) with National Council for Tibb, Pakistan ADMINISTRATIVE RESPONSIBILITIES AND EXPERIENCES Chairman, Department of Eastern Medicine and Surgery, University of Poonch, Rawalakot Azad Kashmir 2015-2017. House Officer at Shifa Ul- Mulk Memorial Hospital, Hamdard University, Karachi 2005 - 06 R. M.O in Shifa Ul- Mulk Memorial Hospital, Hamdard University, Karachi 2006-08 Member of National Curriculum Revision Committee for Bachelor of Eastern Medicine and Surgery, Higher Education Commission, Islamabad-Pakistan Member, Board of Faculty, Faculty of Medical and Health Sciences, University of Poonch, Rawalakot Azad Kashmir Member Board of Studies, Department of Eastern Medicine and Surgery, University of Poonch, Rawalakot, Azad Jammu and Kashmir.
He has published more than 30 scientific publication.